Cargando…

Misoprostol Vaginal Insert in Labor Induction: A Cost–Consequences Model for 5 European Countries—An Economic Evaluation Supported with Literature Review and Retrospective Data Collection

INTRODUCTION: The present study aimed to assess the costs and consequences of using an innovative medical technology, misoprostol vaginal insert (MVI), for the induction of labor (IOL), in place of alternative technologies used as a standard of care. METHODS: This was a retrospective study on cost a...

Descripción completa

Detalles Bibliográficos
Autores principales: Bierut, Adam, Dowgiałło-Smolarczyk, Jadwiga, Pieniążek, Izabela, Stelmachowski, Jarosław, Pacocha, Kinga, Sobkowski, Maciej, Baev, Oleg R., Walczak, Jacek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5055557/
https://www.ncbi.nlm.nih.gov/pubmed/27549327
http://dx.doi.org/10.1007/s12325-016-0397-3
_version_ 1782458776944640000
author Bierut, Adam
Dowgiałło-Smolarczyk, Jadwiga
Pieniążek, Izabela
Stelmachowski, Jarosław
Pacocha, Kinga
Sobkowski, Maciej
Baev, Oleg R.
Walczak, Jacek
author_facet Bierut, Adam
Dowgiałło-Smolarczyk, Jadwiga
Pieniążek, Izabela
Stelmachowski, Jarosław
Pacocha, Kinga
Sobkowski, Maciej
Baev, Oleg R.
Walczak, Jacek
author_sort Bierut, Adam
collection PubMed
description INTRODUCTION: The present study aimed to assess the costs and consequences of using an innovative medical technology, misoprostol vaginal insert (MVI), for the induction of labor (IOL), in place of alternative technologies used as a standard of care. METHODS: This was a retrospective study on cost and resource utilization connected with economic model development. Target population were women with an unfavorable cervix, from 36 weeks of gestation, for whom IOL is clinically indicated. Data on costs and resources was gathered via a dedicated questionnaire, delivered to clinical experts in five EU countries. The five countries participating in the project and providing completed questionnaires were Austria, Poland, Romania, Russia and Slovakia. A targeted literature review in Medline and Cochrane was conducted to identify randomized clinical trials meeting inclusion criteria and to obtain relative effectiveness data on MVI and the alternative technologies. A hospital perspective was considered as most relevant for the study. The economic model was developed to connect data on clinical effectiveness and safety from randomized clinical trials with real life data from local clinical practice. RESULTS: The use of MVI in most scenarios was related to a reduced consumption of hospital staff time and reduced length of patients’ stay in hospital wards, leading to lower total costs with MVI when compared to local comparators. CONCLUSIONS: IOL with the use of MVI generated savings from a hospital perspective in most countries and scenarios, in comparison to alternative technologies. FUNDING: Sponsorship, article processing charges, and the open access charge for this study were funded by Ferring Pharmaceuticals Poland. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s12325-016-0397-3) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5055557
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-50555572016-10-26 Misoprostol Vaginal Insert in Labor Induction: A Cost–Consequences Model for 5 European Countries—An Economic Evaluation Supported with Literature Review and Retrospective Data Collection Bierut, Adam Dowgiałło-Smolarczyk, Jadwiga Pieniążek, Izabela Stelmachowski, Jarosław Pacocha, Kinga Sobkowski, Maciej Baev, Oleg R. Walczak, Jacek Adv Ther Original Research INTRODUCTION: The present study aimed to assess the costs and consequences of using an innovative medical technology, misoprostol vaginal insert (MVI), for the induction of labor (IOL), in place of alternative technologies used as a standard of care. METHODS: This was a retrospective study on cost and resource utilization connected with economic model development. Target population were women with an unfavorable cervix, from 36 weeks of gestation, for whom IOL is clinically indicated. Data on costs and resources was gathered via a dedicated questionnaire, delivered to clinical experts in five EU countries. The five countries participating in the project and providing completed questionnaires were Austria, Poland, Romania, Russia and Slovakia. A targeted literature review in Medline and Cochrane was conducted to identify randomized clinical trials meeting inclusion criteria and to obtain relative effectiveness data on MVI and the alternative technologies. A hospital perspective was considered as most relevant for the study. The economic model was developed to connect data on clinical effectiveness and safety from randomized clinical trials with real life data from local clinical practice. RESULTS: The use of MVI in most scenarios was related to a reduced consumption of hospital staff time and reduced length of patients’ stay in hospital wards, leading to lower total costs with MVI when compared to local comparators. CONCLUSIONS: IOL with the use of MVI generated savings from a hospital perspective in most countries and scenarios, in comparison to alternative technologies. FUNDING: Sponsorship, article processing charges, and the open access charge for this study were funded by Ferring Pharmaceuticals Poland. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s12325-016-0397-3) contains supplementary material, which is available to authorized users. Springer Healthcare 2016-08-22 2016 /pmc/articles/PMC5055557/ /pubmed/27549327 http://dx.doi.org/10.1007/s12325-016-0397-3 Text en © The Author(s) 2016 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Research
Bierut, Adam
Dowgiałło-Smolarczyk, Jadwiga
Pieniążek, Izabela
Stelmachowski, Jarosław
Pacocha, Kinga
Sobkowski, Maciej
Baev, Oleg R.
Walczak, Jacek
Misoprostol Vaginal Insert in Labor Induction: A Cost–Consequences Model for 5 European Countries—An Economic Evaluation Supported with Literature Review and Retrospective Data Collection
title Misoprostol Vaginal Insert in Labor Induction: A Cost–Consequences Model for 5 European Countries—An Economic Evaluation Supported with Literature Review and Retrospective Data Collection
title_full Misoprostol Vaginal Insert in Labor Induction: A Cost–Consequences Model for 5 European Countries—An Economic Evaluation Supported with Literature Review and Retrospective Data Collection
title_fullStr Misoprostol Vaginal Insert in Labor Induction: A Cost–Consequences Model for 5 European Countries—An Economic Evaluation Supported with Literature Review and Retrospective Data Collection
title_full_unstemmed Misoprostol Vaginal Insert in Labor Induction: A Cost–Consequences Model for 5 European Countries—An Economic Evaluation Supported with Literature Review and Retrospective Data Collection
title_short Misoprostol Vaginal Insert in Labor Induction: A Cost–Consequences Model for 5 European Countries—An Economic Evaluation Supported with Literature Review and Retrospective Data Collection
title_sort misoprostol vaginal insert in labor induction: a cost–consequences model for 5 european countries—an economic evaluation supported with literature review and retrospective data collection
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5055557/
https://www.ncbi.nlm.nih.gov/pubmed/27549327
http://dx.doi.org/10.1007/s12325-016-0397-3
work_keys_str_mv AT bierutadam misoprostolvaginalinsertinlaborinductionacostconsequencesmodelfor5europeancountriesaneconomicevaluationsupportedwithliteraturereviewandretrospectivedatacollection
AT dowgiałłosmolarczykjadwiga misoprostolvaginalinsertinlaborinductionacostconsequencesmodelfor5europeancountriesaneconomicevaluationsupportedwithliteraturereviewandretrospectivedatacollection
AT pieniazekizabela misoprostolvaginalinsertinlaborinductionacostconsequencesmodelfor5europeancountriesaneconomicevaluationsupportedwithliteraturereviewandretrospectivedatacollection
AT stelmachowskijarosław misoprostolvaginalinsertinlaborinductionacostconsequencesmodelfor5europeancountriesaneconomicevaluationsupportedwithliteraturereviewandretrospectivedatacollection
AT pacochakinga misoprostolvaginalinsertinlaborinductionacostconsequencesmodelfor5europeancountriesaneconomicevaluationsupportedwithliteraturereviewandretrospectivedatacollection
AT sobkowskimaciej misoprostolvaginalinsertinlaborinductionacostconsequencesmodelfor5europeancountriesaneconomicevaluationsupportedwithliteraturereviewandretrospectivedatacollection
AT baevolegr misoprostolvaginalinsertinlaborinductionacostconsequencesmodelfor5europeancountriesaneconomicevaluationsupportedwithliteraturereviewandretrospectivedatacollection
AT walczakjacek misoprostolvaginalinsertinlaborinductionacostconsequencesmodelfor5europeancountriesaneconomicevaluationsupportedwithliteraturereviewandretrospectivedatacollection